# Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients

> **NCT01822080** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 250 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Dienogest (Visanne, BAY86-5258)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01822080
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-11
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2015-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822080, "Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01822080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*